Under the deal, NAMSA will take control of WuXi’s facilities in the US states of Minnesota and Georgia. Image credit: K illustrator Photo via Shutterstock

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities.

The deal, for which the financial terms have not been disclosed, will see the CRO take control of WuXi’s facilities in the US states of Minnesota and Georgia. The China-headquartered company provides R&D and manufacturing services to the life sciences industry.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Dechert LLP served as legal advisor to NAMSA on the agreement.

NAMSA CEO André-Michel Ballester said: “We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients.

“NAMSA and WuXi AppTec’s medical device testing operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating medtech innovation and helping sponsors deliver life-saving medical technology throughout the world.”

Established in 1967, NAMSA specialises in testing medical device materials for safety. France-based ArchiMed Group acquired a majority stake in the company in 2020 and, in 2022, an affiliate of ArchiMed signed a $1.2bn deal to acquire healthcare solutions provider Natus Medical.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This week has seen the launch of a new pan-European initiative aimed at creating a less fragmented and more democratic ecosystem for clinical trials across the continent.

Comprising CROs and hospital sites across Europe, the consortium, dubbed Research in Europe and Diversity Inclusion (READI), is backed by 73 continental healthcare entities and industry players that include Novo Nordisk, AbbVie, and Roche. The consortium is led by the Servicio Madrileño de Salud (SERMAS) based out of the Spanish University Hospital of La Paz.